NOVARTIS AG

Novartis faces a setback as Pelacarsen fails to meet Phase 3 goals, dampening investor confidence and prompting a rethink of its gene‑silencing strategy.

Novartis’s shares tumble after Phase III failures in del‑desiran for DM1 and pelacarsen for LDL, highlighting risks for a $6 billion‑plus market opportunity.

Novartis stock jumps 6% as MS trial success and remibrutinib Phase III results boost investor confidence, amid a $3.2 bn licensing deal with Alteogen.

Novartis raises 2026 outlook, boosting revenue and profit forecasts amid strong growth and investor confidence.

Novartis AG: Mixed analyst sentiment, solid pipeline, and resilient portfolio – a balanced view for long‑term investors and traders alike.

Novartis AG remains a Swiss pharma powerhouse amid market volatility, showcasing strong growth, a robust pipeline, and resilient investor confidence.

Novartis expands U.S. production with a new Texas plant, boosting prescription and generic capacity while streamlining supply chains for cardiovascular, oncology and immunology therapies.

Novartis’ dual thrust—Fabhalta’s 49% kidney‑slowdown efficacy and a $2 bn Excellergy anti‑IgE deal—boosts its portfolio, revenue outlook and investor confidence.

Novartis secures FDA approval for Cosentyx in children ≥12 with severe hidradenitis suppurativa, opening new therapeutic and market opportunities.

Novartis releases real‑world evidence boosting Pluvicto’s use for metastatic prostate cancer and faces shareholder‑driven CEO compensation review.